Lonza Group AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
Moderna has updated its protocol, expanding its recruitment target to 30,000 and aiming for more ethnically diverse and at-risk groups to be included.
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
Moderna's Bencal and Merck Vaccine head Markels discuss the difficulties in scaling up manufacturing capacity for vaccine candidates at BIO plenary session; CEPI CEO says his organization can help facilitate pairing of vaccine development partners.
The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.